Theravance Biopharma (TBPH) Price & Analysis

Compare

316 Followers

TBPH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.88 - $14.30

Previous CloseN/A

Volume28.33K

Average Volume (3M)351.86K

Market Cap

$694.99M

Enterprise Value$267.16M

Total Cash (Recent Filing)$338.80M

Total Debt (Recent Filing)$46.46M

Price to Earnings (P/E)59.0

Beta0.98

Next Earnings

Nov 05, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.08

Shares Outstanding50,361,298

10 Day Avg. Volume612,637

30 Day Avg. Volume351,862

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue3.46

Enterprise Value/Gross Profit3.46

Enterprise Value/Ebitda5.80

Forecast

1Y Price Target

$17.83

Price Target Upside29.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommendation is a 'Buy' for Theravance Biopharma stock with a price target of 24.00.

Clinical Trial ResultsThe CYPRESS trial is significantly de-risked by preceding Phase 3 results where ampreloxetine showed positive trends without worsening of supine hypertension.

Market NeedA large majority of MSA patients with neurogenic orthostatic hypotension require pharmacologic treatment, indicating a strong market need.

Bears Say

Current Treatment LimitationsCurrently available treatment options are inadequate for up to 70% of patients, highlighting a gap in effective solutions.

Patient Management ChallengesAbout 50% of patients develop treatment limiting supine hypertension.

Theravance Biopharma News

Theravance Biopharma completes enrollment in CYPRESS study

Theravance Biopharma (TBPH) announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study...

4d ago

TBPH

Theravance Biopharma reports Q2 EPS $1.08 with items, consensus (12c)

Reports Q2 revenue $26.2M, consensus $26.03M. Reports Q2 Non-GAAP net loss from operations $4.2M vs. a net loss...

16d ago

TBPH

Theravance Biopharma reaffirms FY25 R&D expenses view $32M-$38M

Reaffirms FY25 SG&A expenses view $50M-$60M excluding share-based compensation. Reaffirms FY25 share-based compensation expenses view $18M-$20M; and Non-GAAP...

16d ago

TBPH

Promising Outlook for Theravance Biopharma: Buy Rating Backed by Phase 3 CYPRESS Trial Developments

Analyst Julian Harrison from BTIG maintained a Buy rating on Theravance Biopharma and keeping the price target at...

3d ago

TBPH

Theravance Completes Enrollment in Phase 3 CYPRESS Study

An announcement from Theravance Biopharma ( ($TBPH) ) is now available. On August 25, 2025, Theravance Biopharma announced...

4d ago

TBPH

Theravance Biopharma Settles Patent Dispute with Cipla

An update from Theravance Biopharma ( ($TBPH) ) is now available. On August 15, 2025, Theravance Biopharma and...

9d ago

TBPH

Theravance Biopharma: Strong Product Performance and Promising Growth Prospects Justify Buy Rating

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on TBPH stock, giving a Buy rating on August...

13d ago

TBPH

Theravance Biopharma’s Earnings Call Highlights Strategic Gains

Theravance Biopharma (($TBPH)) has held its Q2 earnings call. Read on for the main highlights of the call....

15d ago

TBPH

Theravance Biopharma’s Strong Growth Potential Backed by Yupelri Success and Pipeline Advancements

Analyst Julian Harrison of BTIG maintained a Buy rating on Theravance Biopharma, retaining the price target of $25.00....

16d ago

TBPH

Theravance Biopharma Reports Strong Q2 2025 Results

Theravance Biopharma ( ($TBPH) ) has released its Q2 earnings. Here is a breakdown of the information Theravance...

16d ago

TBPH

Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty

Analyst Marc Frahm from TD Cowen maintained a Hold rating on Theravance Biopharma and increased the price target...

16d ago

TBPH

TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Theravance Biopharma (TBPH) is scheduled to report 2nd quarter earnings on 08/12/2025, after the market closes. Regarding Q2...

19d ago

TBPH

Theravance Biopharma price target raised to $25 from $24 at BTIG

BTIG raised the firm’s price target on Theravance Biopharma (TBPH) to $25 from $24 and keeps a Buy...

2M ago

TBPH

Theravance Biopharma Gains Milestone Payment from Viatris

Theravance Biopharma ( ($TBPH) ) has provided an announcement. On June 26, 2025, Theravance Biopharma announced that Viatris...

2M ago

TBPH

TBPH FAQ

What was Theravance Biopharma’s price range in the past 12 months?

Theravance Biopharma lowest stock price was $7.88 and its highest was $14.30 in the past 12 months.

What is Theravance Biopharma’s market cap?

Theravance Biopharma’s market cap is $694.99M.

When is Theravance Biopharma’s upcoming earnings report date?

Theravance Biopharma’s upcoming earnings report date is Nov 05, 2025 which is in 68 days.

How were Theravance Biopharma’s earnings last quarter?

Theravance Biopharma released its earnings results on Aug 12, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.673 by $0.407.

Is Theravance Biopharma overvalued?

According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Theravance Biopharma pay dividends?

Theravance Biopharma does not currently pay dividends.

What is Theravance Biopharma’s EPS estimate?

Theravance Biopharma’s EPS estimate is -0.13.

How many shares outstanding does Theravance Biopharma have?

Theravance Biopharma has 50,361,298 shares outstanding.

What happened to Theravance Biopharma’s price movement after its last earnings report?

Theravance Biopharma reported an EPS of $1.08 in its last earnings report, beating expectations of $0.673. Following the earnings report the stock price went up 4.195%.

Which hedge fund is a major shareholder of Theravance Biopharma?

Currently, no hedge funds are holding shares in TBPH

Theravance Biopharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

6.23%

Trailing 12-Months

Asset Growth

17.68%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company focused on developing innovative medicines for serious illnesses, particularly in the areas of respiratory and gastrointestinal diseases. The company operates primarily in the pharmaceutical sector, with a portfolio that includes a range of products designed to address unmet medical needs. Its lead product, Vibativ (telavancin), is an injectable antibiotic used for the treatment of certain infections, and the company is actively engaged in the research and development of novel therapeutics targeting various conditions.

Theravance Biopharma (TBPH) Earnings & Revenues

Historic Earnings Reports

TBPH Company Deck

TBPH Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call showcased a strong financial performance with significant growth in YUPELRI sales and strategic financial transactions that bolster Theravance's balance sheet. The advancement of the ampreloxetine trial and strong TRELEGY performance add to the positive outlook. However, uncertainties around YUPELRI's launch in China and tax liabilities from recent transactions were noted as slight concerns.View all TBPH earnings summaries

TBPH Stock 12 Month Forecast

Average Price Target

$17.83

▲(29.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","12":"$12","17":"$17","22":"$22","27":"$27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12,17,22,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,12.061538461538461,13.223076923076924,14.384615384615385,15.546153846153846,16.707692307692305,17.869230769230768,19.03076923076923,20.192307692307693,21.353846153846153,22.515384615384612,23.676923076923075,24.838461538461537,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,11.433076923076923,11.966153846153846,12.499230769230769,13.032307692307691,13.565384615384614,14.098461538461539,14.631538461538462,15.164615384615384,15.697692307692307,16.23076923076923,16.763846153846153,17.296923076923076,{"y":17.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.9,11.061538461538461,11.223076923076924,11.384615384615385,11.546153846153846,11.707692307692309,11.86923076923077,12.03076923076923,12.192307692307693,12.353846153846154,12.515384615384615,12.676923076923078,12.838461538461539,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.03,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.84,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.03,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >